Gyre Therapeutics, Inc. (GYRE) shareholders
Close on Nov 18, 2026Market cap $483.95MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| GNI USA, Inc. Joint filing with GNI Group Ltd. (69.10%) | 86,323,015 | 69.10% | 13D (active) amendment | May 4, 2026 |
| Ying Luo Joint filing with Ping Lan (8.60%) | 10,211,387 | 8.60% | 13D (active) amendment | May 4, 2026 |
| Songjiang Ma Joint filing with Yueying Zhu (6.33%) | 7,342,131 | 6.33% | 13D (active) amendment | May 4, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of GYRE | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| HSG Holding Ltd | 3,750,299 | 3.36% | $24.71M | New | 1.99% |
| BlackRock, Inc. | 993,943 | 0.89% | $6.55M | +235,313 | 0.00% |
| Octagon Capital Advisors LP | 954,416 | 0.86% | $6.29M | New | 0.57% |
| Vanguard Capital Management LLC | 876,927 | 0.79% | $5.78M | −107,277 | 0.00% |
| Geode Capital Management, LLC | 532,950 | 0.48% | $3.51M | +101,536 | 0.00% |
| State Street Corp | 245,402 | 0.22% | $1.62M | +29,076 | 0.00% |
| Charles Schwab Investment Management Inc | 184,286 | 0.17% | $1.21M | +19,048 | 0.00% |
| Northern Trust Corp | 169,537 | 0.15% | $1.12M | +35,696 | 0.00% |
| SBI Securities Co., Ltd. | 166,750 | 0.15% | $1.10M | −4,087 | 0.02% |
| Vanguard Fiduciary Trust Co | 151,073 | 0.14% | $995.57K | +13,391 | 0.00% |
| Vanguard Portfolio Management LLC | 123,953 | 0.11% | $816.85K | +54,139 | 0.00% |
| Goldman Sachs Group Inc | 86,235 | 0.08% | $568.29K | +13,113 | 0.00% |
| Bank of New York Mellon Corp | 62,750 | 0.06% | $413.52K | +19,606 | 0.00% |
| Morgan Stanley | 41,691 | 0.04% | $274.74K | +33,050 | 0.00% |
| Strs Ohio | 25,800 | 0.02% | $170.02K | +4,700 | 0.00% |
| Dimensional Fund Advisors LP | 25,268 | 0.02% | $166.52K | – | 0.00% |
| Alliancebernstein L.P. | 24,590 | 0.02% | $171.39K | +2,760 | 0.00% |
| Nuveen, LLC | 24,505 | 0.02% | $161.49K | New | 0.00% |
| UBS Group AG | 18,763 | 0.02% | $123.65K | −2,324 | 0.00% |
| Millennium Management LLC | 18,488 | 0.02% | $121.84K | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 60 | 9M | 7.8% | 12 / 31 | 9 / 7 | 5M | 0M |
| Q1 2026 | 56 | 3M | 3.1% | 15 / 18 | 11 / 2 | 1M | 0M |
| Q4 2025 | 44 | 3M | 3.0% | 2 / 22 | 9 / 6 | 0M | 0M |
| Q3 2025 | 48 | 3M | 2.8% | 10 / 13 | 16 / 10 | 0M | 0M |
| Q2 2025 | 48 | 3M | 3.1% | 10 / 25 | 8 / 7 | 1M | 0M |
| Q1 2025 | 45 | 3M | 2.3% | 8 / 15 | 14 / 3 | 1M | 0M |
| Q4 2024 | 40 | 2M | 1.6% | 5 / 16 | 12 / 2 | 0M | 0M |
| Q3 2024 | 37 | 2M | 1.4% | 12 / 14 | 6 / 4 | 1M | 0M |
| Q2 2024 | 30 | 1M | 1.1% | 16 / 7 | 6 / 7 | 1M | 0M |
| Q1 2024 | 21 | 1M | 0.8% | 10 / 6 | 4 / 4 | 0M | 0M |
| Q4 2023 | 15 | 1M | 0.5% | 15 / 0 | 0 / 0 | 1M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
76 funds held GYRE in Q2 2026, 71% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of GYRE | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 614,654 | 0.55% | $4.05M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 394,330 | 0.35% | $2.60M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 238,693 | 0.21% | $1.57M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 199,906 | 0.18% | $1.15M | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 120,729 | 0.11% | $795.60K | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 111,244 | 0.10% | $657.45K | 0.00% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 99,892 | 0.09% | $590.36K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 60,238 | 0.05% | $356.01K | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 60,098 | 0.05% | $355.18K | 0.00% | May 31, 2026 |
| Schwab Small-Cap Index Fund | 44,877 | 0.04% | $258.04K | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 41,653 | 0.04% | $274.49K | 0.00% | Jun 30, 2026 |
| Master Small Cap Index Series | 41,616 | 0.04% | $274.25K | 0.00% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 37,509 | 0.03% | $221.68K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 31,953 | 0.03% | $188.84K | 0.00% | May 31, 2026 |
| Nuveen Small Cap Blend Index Fund | 24,505 | 0.02% | $140.90K | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Ying Luo | Chief Executive Officer, Director | 2,565,226 | 2.30% | Jun 10, 2026 |
| Songjiang Ma | President, Director | 2,806,084 | 2.52% | May 29, 2025 |
| Weiguo Ye | Chief Operating Officer | 700,000 | 0.63% | Jun 22, 2026 |
| Joshua Benjamin Bergmann | GC and Corporate Secretary | – | – | Jun 10, 2026 |
| Jialiang (NMN) Wang | EVP, General Manager | – | – | May 7, 2026 |
| Yue Xiong | Chief Scientific Officer | – | – | May 7, 2026 |
| Thomas Wilson Eastling | Chief Financial Officer | 15,000 | 0.01% | May 6, 2026 |
| Ruoyu Chen | Chief Financial Officer | – | – | Jan 9, 2026 |
| Maxwell Kirkby | Director | – | – | Aug 4, 2026 |
| Claire Weston | Director | – | – | Aug 4, 2026 |
| Renate Parry | Director | – | – | Jun 30, 2026 |
| Rodney L. Nussbaum | Director | – | – | Jun 30, 2026 |
| Dan Weng | Director | – | – | Jun 30, 2026 |
| Ping Zhang | Director | – | – | Jun 30, 2026 |
| Gordon Carmichael | Director | – | – | Jun 30, 2026 |
| David M. Epstein | Director | – | – | Jun 30, 2026 |
| GNI USA, Inc. | 10% owner | 64,005,887 | 57.40% | May 6, 2026 |
| Group Ltd. GNI | 10% owner | 6,266,521 | 5.62% | May 6, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Weiguo Ye Chief Operating Officer | Jun 18, 2026 | Sale | −3,000 | $6.35 | $19.05K | 700,000 |
| Weiguo Ye Chief Operating Officer | Jun 18, 2026 | Option exercise | +3,000 | $0.75 | $2.25K | 703,000 |
| Weiguo Ye Chief Operating Officer | Jun 11, 2026 | Sale | −2,800 | $6.17 | $17.28K | 700,000 |
| Weiguo Ye Chief Operating Officer | Jun 11, 2026 | Option exercise | +2,800 | $0.75 | $2.10K | 702,800 |
| Weiguo Ye Chief Operating Officer | Jun 10, 2026 | Option exercise | +5,000 | $0.75 | $3.75K | 705,000 |
| Weiguo Ye Chief Operating Officer | Jun 10, 2026 | Sale | −5,000 | $6.24 | $31.20K | 700,000 |
| Weiguo Ye Chief Operating Officer | Jun 10, 2026 | Sale | −6,418 | $6.21 | $39.86K | 700,000 |
| Weiguo Ye Chief Operating Officer | Jun 10, 2026 | Option exercise | +6,418 | $0.75 | $4.81K | 706,418 |
| Weiguo Ye Chief Operating Officer | Jun 9, 2026 | Option exercise | +3,000 | $0.75 | $2.25K | 703,000 |
| Weiguo Ye Chief Operating Officer | Jun 9, 2026 | Sale | −3,000 | $6.15 | $18.45K | 700,000 |
| Weiguo Ye Chief Operating Officer | Jun 9, 2026 | Sale | −14,500 | $6.14 | $89.03K | 700,000 |
| Weiguo Ye Chief Operating Officer | Jun 9, 2026 | Option exercise | +14,500 | $0.75 | $10.88K | 714,500 |
| Weiguo Ye Chief Operating Officer | Jun 5, 2026 | Option exercise | +15,401 | $0.75 | $11.55K | 715,401 |
| Weiguo Ye Chief Operating Officer | Jun 5, 2026 | Sale | −15,401 | $6.40 | $98.57K | 700,000 |
| Weiguo Ye Chief Operating Officer | Jun 4, 2026 | Option exercise | +19,575 | $0.75 | $14.68K | 719,575 |
| Weiguo Ye Chief Operating Officer | Jun 4, 2026 | Sale | −19,575 | $6.13 | $119.99K | 700,000 |
| Weiguo Ye Chief Operating Officer | May 26, 2026 | Option exercise | +4,000 | $0.75 | $3.00K | 704,000 |
| Weiguo Ye Chief Operating Officer | May 26, 2026 | Sale | −4,000 | $6.10 | $24.40K | 700,000 |
| Weiguo Ye Chief Operating Officer | May 22, 2026 | Option exercise | +3,500 | $0.75 | $2.63K | 703,500 |
| Weiguo Ye Chief Operating Officer | May 22, 2026 | Sale | −3,500 | $6.08 | $21.28K | 700,000 |
| Weiguo Ye Chief Operating Officer | May 21, 2026 | Sale | −12,820 | $6.15 | $78.84K | 700,000 |
| Weiguo Ye Chief Operating Officer | May 21, 2026 | Option exercise | +12,820 | $0.75 | $9.62K | 712,820 |
| Weiguo Ye Chief Operating Officer | May 20, 2026 | Sale | −9,400 | $6.15 | $57.81K | 700,000 |
| Weiguo Ye Chief Operating Officer | May 20, 2026 | Option exercise | +9,400 | $0.75 | $7.05K | 709,400 |
| Weiguo Ye Chief Operating Officer | May 19, 2026 | Option exercise | +9,120 | $0.75 | $6.84K | 709,120 |
| Weiguo Ye Chief Operating Officer | May 19, 2026 | Sale | −9,120 | $6.37 | $58.09K | 700,000 |
| Weiguo Ye Chief Operating Officer | May 18, 2026 | Sale | −200 | $6.62 | $1.32K | 700,000 |
| Weiguo Ye Chief Operating Officer | May 18, 2026 | Option exercise | +200 | $0.75 | $150 | 700,200 |
| Weiguo Ye Chief Operating Officer | May 15, 2026 | Option exercise | +13,100 | $0.75 | $9.83K | 713,100 |
| Weiguo Ye Chief Operating Officer | May 15, 2026 | Sale | −13,100 | $6.65 | $87.12K | 700,000 |
| Weiguo Ye Chief Operating Officer | May 14, 2026 | Sale | −15,580 | $6.91 | $107.66K | 700,000 |
| Weiguo Ye Chief Operating Officer | May 14, 2026 | Option exercise | +15,580 | $0.75 | $11.69K | 715,580 |
| Ying Luo Chief Executive Officer, Director | May 6, 2026 | Sale(10b5-1 plan) | −10,136 | $8.04 | $81.49K | 2,565,226 |
| Ying Luo Chief Executive Officer, Director | May 5, 2026 | Sale(10b5-1 plan) | −179 | $8.01 | $1.43K | 2,575,362 |
| Songjiang Ma President, Director | May 28, 2025 | Sale(10b5-1 plan) | −558 | $10.07 | $5.62K | 2,806,084 |
| Songjiang Ma President, Director | May 27, 2025 | Sale(10b5-1 plan) | −2,000 | $10.28 | $20.56K | 2,806,642 |
| Songjiang Ma President, Director | May 23, 2025 | Sale(10b5-1 plan) | −182 | $10.24 | $1.86K | 2,808,642 |
| Songjiang Ma President, Director | May 22, 2025 | Sale(10b5-1 plan) | −2,000 | $10.97 | $21.94K | 2,808,824 |
| Songjiang Ma President, Director | May 21, 2025 | Sale(10b5-1 plan) | −2,000 | $10.83 | $21.66K | 2,810,824 |
| Songjiang Ma President, Director | May 20, 2025 | Sale(10b5-1 plan) | −2,000 | $11.25 | $22.50K | 2,812,824 |
| Songjiang Ma President, Director | May 19, 2025 | Sale(10b5-1 plan) | −2,000 | $11.11 | $22.22K | 2,814,824 |
| Songjiang Ma President, Director | May 16, 2025 | Sale(10b5-1 plan) | −2,000 | $11.31 | $22.62K | 2,816,824 |
| Songjiang Ma President, Director | May 15, 2025 | Sale(10b5-1 plan) | −2,000 | $10.68 | $21.36K | 2,818,824 |
| Songjiang Ma President, Director | May 14, 2025 | Sale(10b5-1 plan) | −20 | $11.30 | $226 | 2,820,824 |
| Songjiang Ma President, Director | May 13, 2025 | Sale(10b5-1 plan) | −2,000 | $11.37 | $22.74K | 2,820,844 |
| Songjiang Ma President, Director | May 12, 2025 | Sale(10b5-1 plan) | −2,000 | $10.56 | $21.12K | 2,822,844 |
| Thomas Wilson Eastling Director | Apr 16, 2025 | Option exercise | +15,000 | $6.93 | $103.95K | 15,000 |
| Weiguo Ye Chief Operating Officer | Apr 1, 2025 | Option exercise | +50,000 | $0.75 | $37.50K | 700,000 |
| Weiguo Ye Chief Operating Officer | Mar 27, 2025 | Option exercise | +150,000 | $0.75 | $112.50K | 650,000 |
| Weiguo Ye Chief Operating Officer | Mar 26, 2025 | Option exercise | +200,000 | $0.75 | $150.00K | 500,000 |
| Weiguo Ye Chief Operating Officer | Mar 24, 2025 | Option exercise | +300,000 | $0.75 | $225.00K | 300,000 |
| Songjiang Ma President, Director | Mar 21, 2025 | Sale(10b5-1 plan) | −174 | $10.00 | $1.74K | 2,824,844 |
| Songjiang Ma President, Director | Mar 20, 2025 | Sale(10b5-1 plan) | −2,000 | $10.09 | $20.18K | 2,825,018 |
| Songjiang Ma President, Director | Mar 19, 2025 | Sale(10b5-1 plan) | −2,000 | $10.13 | $20.26K | 2,827,018 |
| Songjiang Ma President, Director | Mar 18, 2025 | Sale(10b5-1 plan) | −242 | $10.24 | $2.48K | 2,829,018 |
| Songjiang Ma President, Director | Mar 17, 2025 | Sale(10b5-1 plan) | −2,000 | $12.09 | $24.18K | 2,829,260 |
| Songjiang Ma President, Director | Mar 14, 2025 | Sale(10b5-1 plan) | −2,000 | $12.31 | $24.62K | 2,831,260 |
| Songjiang Ma President, Director | Mar 13, 2025 | Sale(10b5-1 plan) | −2,000 | $11.80 | $23.60K | 2,833,260 |
| Songjiang Ma President, Director | Mar 12, 2025 | Sale(10b5-1 plan) | −2,000 | $11.74 | $23.48K | 2,835,260 |
| Songjiang Ma President, Director | Mar 11, 2025 | Sale(10b5-1 plan) | −2,000 | $11.40 | $22.80K | 2,837,260 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Gyre Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 10,195 shares on Sep 28, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Weiguo Ye Officer | May 11, 2026 | 300,000 | $2.12M | May 13, 2026 | Stock Option Exercise |
| Weiguo Ye Officer | Nov 13, 2025 | 548,000 | $4.57M | Nov 15, 2025 | Stock Option Exercise |
| Nassim Usman Director | Jul 18, 2024 | 633 | $9.67K | Jul 18, 2024 | Stock Option Exercise |
| Nassim Usman Director | Jul 17, 2024 | 3,347 | $51.33K | Jul 17, 2024 | Stock Option Exercise |
| Nassim Usman Director | Jul 16, 2024 | 100 | $1.42K | Jul 16, 2024 | Stock Option Exercise |
| Nassim Usman Director | Jul 15, 2024 | 4,900 | $68.99K | Jul 15, 2024 | Stock Option Exercise |
| Nassim Usman Director | Jul 3, 2024 | 33 | $396 | Jul 3, 2024 | Stock Option Exercise |
| Nassim Usman Director | Jul 2, 2024 | 7,767 | $93.99K | Jul 2, 2024 | Stock Option Exercise |
| Nassim Usman Director | Jul 1, 2024 | 12,200 | $148.10K | Jul 1, 2024 | Stock Option Exercise |
| Nassim Usman Director | Jun 28, 2024 | 3,452 | $41.44K | Jun 28, 2024 | Stock Option Exercise |
| Nassim Usman Director | May 1, 2024 | 20,000 | $282.47K | May 1, 2024 | Stock Option Exercise |
| Charles C. Wu Officer, Director | Apr 9, 2024 | 2,154 | $36.68K | Apr 9, 2024 | Stock Option Exercise |
| Charles C. Wu Officer, Director | Apr 8, 2024 | 2,966 | $50.49K | Apr 8, 2024 | Stock Option Exercise |
| Charles C. Wu Officer, Director | Apr 5, 2024 | 1,412 | $24.05K | Apr 5, 2024 | Stock Option Exercise |
| Charles C. Wu Officer, Director | Apr 4, 2024 | 777 | $13.43K | Apr 4, 2024 | Stock Option Exercise |
See a number that looks wrong?